Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase inhibitor HBI-8000 has succeeded in combination with Bristol Myers Squibb’s Opdivo in a phase 3 trial of patients with advanced skin cancer.

In the second of a new series of interviews with top executives from leading healthcare and comms agencies, Fierce Pharma Marketing sat down with London-based Havas SO’s managing director, Joanna Quade and Creative Director, Lucy Doolan.

Senior Director Kate Woda breaks down what attendees can expect at the Partnerships with Sites Summit, happening Sept. 14, 2026 in Boston, MA.

The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients with breast cancer.

AstraZeneca is shelling out up to $1.5 billion to lock down global rights to an EGFR lung cancer drug from Dizal Pharmaceutical, deepening its ties with a Chinese biotech it spun out nearly a decade ago.

Real Chemistry has launched artificial intelligence tools for healthcare commercialization, continuing its embrace of technology tipped to transform biopharma marketing.